Log in

Relevant bibliographies by topics / Inhibiteurs de JAK/STAT / Books

Books on the topic 'Inhibiteurs de JAK/STAT'

To see the other types of publications on this topic, follow the link: Inhibiteurs de JAK/STAT.

Author: Grafiati

Published: 22 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 26 books for your research on the topic 'Inhibiteurs de JAK/STAT.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Nicholson, Sandra E., and Nicos A. Nicola, eds. JAK-STAT Signalling. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-242-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Anastasis, Stephanou, ed. JAK-STAT pathway in disease. Austin, Tex: Landes Bioscience, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Decker, Thomas, and Mathias Müller, eds. Jak-Stat Signaling : From Basics to Disease. Vienna: Springer Vienna, 2012. http://dx.doi.org/10.1007/978-3-7091-0891-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wilks, Andrew F., and Ailsa G. Harpur. Intracellular Signal Transduction: The JAK-STAT Pathway. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-662-22050-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wilks, Andrew F. Intracellular signal transduction: The JAK-STAT pathway. New York: Springer, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. CRC Press, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stephanou, Anastasis, and Bell Richard H. Jr. JAK-STAT Pathway in Disease. Taylor & Francis Group, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

H, Bell Jr Richard. JAK-STAT Pathway in Disease. Taylor & Francis Group, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Goswami, Ritobrata. JAK-STAT Signaling in Diseases. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Nicola, Nicos A., and Sandra E. Nicholson. JAK-STAT Signalling: Methods and Protocols. Humana Press, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Decker, Thomas, and Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Harpur, Ailsa G., and Andrew F. Wilks. Intracellular Signal Transduction: The JAK-STAT Pathway. Springer, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Decker, Thomas, and Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Decker, Thomas, and Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Decker, Thomas, and Mathias Müller. Jak-Stat Signaling: From Basics to Disease. Springer Wien, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Wilks, Andrew F. Intracellular Signal Transduction: The Jak-Stat Pathway. Springer, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

The Jak-Stat pathway in hematopoiesis and disease. Georgetown, Tex: Landes Bioscience/Eurekah.com, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Harpur, Ailsa G., and Andrew F. Wilks. The Jak-Stat Pathway (Molecular Biology Intelligence Unit). Springer, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ward, Alister C. The Jak-Stat Pathway in Hematopoiesis and Disease (Molecular Biology Intelligence Unit, 20). Springer, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ng, Sze-Ling. The Role of IKKepsilon in JAK/STAT Signaling During the Antiviral Immune Response. 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mahdavi, Alborz. Analysis of transient JAK/STAT signaling kinetics predicts control modules of stem cell fate control. 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Jakstat Signalling Methods And Protocols. Humana Press, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Fostamatinib disodium is an orally available inhibitor of spleen tyrosine kinase (SyK), which is a cytoplasmic tyrosine kinase that is an important mediator of immunoreceptor signalling in mast cells, macrophages, neutrophils, and B cells. Interruption of SyK signalling may interrupt production of tumour necrosis factor (TNF) and metalloproteinase and therefore affect RA disease activity. Tofacitinib has been investigated in multiple phase 2 and phase 3 trials which have investigated its efficacy (clinical, functional, and radiographic) and safety in patients who have failed disease-modifying anti-inflammatory drugs (DMARDs) as monotherapy or in combination with DMARDs, compared to an inhibitor of tumour necrosis factor alpha (TNFα‎) and in patients who have failed TNFα‎ inhibitors. The efficacy of fostamatinib and baricitinib has been investigated in phase 2 trials; both are in large phase 3 clinical programmes. Each of these medications has demonstrated efficacy; their safety profile has been shown to be different from each other and from currently approved biological agents. This chapter discusses what is currently known and understood about their efficacy and safety.